Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyperlipidaemia and hypertension.

W Krone, D Müller-Wieland

    Bailliere'S Clinical Endocrinology and Metabolism
    |December 1, 1990
    PubMed
    Summary
    This summary is machine-generated.

    Managing hyperlipidaemia and hypertension is crucial for preventing cardiovascular disease. Early identification and comprehensive treatment, including lifestyle changes and targeted medications, are key for high-risk patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Juvenile nasopharyngeal angiofibroma: nationwide study on incidence, diagnosis, treatment, and recurrence.

    Rhinology·2026
    Same author

    Digital intervention increases influenza vaccination rates for people with diabetes in a decentralized randomized trial.

    NPJ digital medicine·2021
    Same author

    Glycaemic Control in Diabetes.

    Handbook of experimental pharmacology·2021
    Same author

    The natural history of classic galactosemia: lessons from the GalNet registry.

    Orphanet journal of rare diseases·2019
    Same author

    [Cardiovascular risk in gout patients : Cardiovascular Safety of Febuxostat or Allopurinol in Participants with Gout and Cardiovascular Comorbidities (CARES)].

    Der Internist·2018
    Same author

    Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials.

    Diabetic medicine : a journal of the British Diabetic Association·2017
    Same journal

    Phytoestrogen content in foods.

    Bailliere's clinical endocrinology and metabolism·1999
    Same journal

    Soyfoods, isoflavones and risk of colonic cancer: a review of the in vitro and in vivo data.

    Bailliere's clinical endocrinology and metabolism·1999
    Same journal

    Experimental studies on lignans and cancer.

    Bailliere's clinical endocrinology and metabolism·1999
    Same journal

    Reproductive actions of phytoestrogens.

    Bailliere's clinical endocrinology and metabolism·1999
    Same journal

    Phytoestrogens and inhibition of angiogenesis.

    Bailliere's clinical endocrinology and metabolism·1999
    Same journal

    Phytoestrogens and diseases of the prostate gland.

    Bailliere's clinical endocrinology and metabolism·1999
    See all related articles

    Area of Science:

    • Cardiology
    • Internal Medicine
    • Public Health

    Background:

    • Hyperlipidaemia and hypertension are prevalent risk factors for cardiovascular complications.
    • Their combined presence significantly elevates cardiovascular risk, necessitating early identification and management.
    • Effective treatment aims to mitigate serious health outcomes in high-risk individuals.

    Purpose of the Study:

    • To outline the importance of managing combined hyperlipidaemia and hypertension.
    • To define target blood pressure and lipid levels for high-risk patients.
    • To discuss therapeutic strategies for this patient group.

    Main Methods:

    • Review of current guidelines and therapeutic approaches for hypertension and hyperlipidaemia.
    • Emphasis on non-pharmacological interventions such as weight reduction, dietary changes, smoking cessation, and increased physical activity.

    Related Experiment Videos

  • Discussion of pharmacological options, prioritizing antihypertensives with neutral lipid effects and bile acid sequestrants or HMG CoA reductase inhibitors for hypercholesterolaemia.

    • Main Results:

    • Target blood pressure: diastolic < 90 mm Hg, systolic < 140 mm Hg.
    • Target lipid levels: total cholesterol ≤ 200 mg/dl, LDL cholesterol ≤ 135 mg/dl, triglycerides ≤ 200 mg/dl.
    • Non-pharmacological measures are the first line of treatment, followed by appropriate pharmacological interventions.

    Conclusions:

    • Integrated management of hyperlipidaemia and hypertension is essential for cardiovascular risk reduction.
    • Lifestyle modifications are foundational, supplemented by pharmacotherapy when necessary.
    • Careful drug selection is important to avoid adverse effects on lipid profiles.